Marek Feith, Saikat Das Sajib, Anne Grethe Myrann, Anders Høgset, Pablo Garrido, Alfredo Martinez, Erik Knutsen, Kirsten Sandvig, Tore Skotland, Gunhild Mari Mælandsmo, Tore-Geir Iversen
{"title":"Induction of Cell Death by Combined Treatment with Photosensitizer-Chitosan Nanoparticles and the Ferroptosis Inducer RSL3 in Breast Cancer Cell Lines","authors":"Marek Feith, Saikat Das Sajib, Anne Grethe Myrann, Anders Høgset, Pablo Garrido, Alfredo Martinez, Erik Knutsen, Kirsten Sandvig, Tore Skotland, Gunhild Mari Mælandsmo, Tore-Geir Iversen","doi":"10.1002/anbr.202400208","DOIUrl":null,"url":null,"abstract":"<p>\nBreast cancer, a prevalent malignancy worldwide, includes the triple-negative subtype (TNBC) characterized by poor treatment outcomes. TNBC has been shown to be sensitive to ferroptotic cell death, an iron-dependent cell death mechanism involving reactive oxygen species (ROS) and lipid peroxidation. Herein, biodegradable tetraphenylchlorin-conjugated chitosan nanoparticles (TPC-CS NPs) in combination with the free ferroptosis inducer RSL3 is used in MCF7 (hormone receptor-positive, epithelial) and MDA-MB-231 (hormone receptor-negative, mesenchymal-like) breast cancer cell lines. The results show that RSL3 treatment has no cytotoxic effect in MCF7 and there is no enhanced sensitivity when combined with TPC-CS NPs, while the combination sensitizes MDA-MB-231 cells. Western blot analysis reveals that the combined treatment decreases and differently affects GPX4 levels and the ratio between the two GPX isoforms in the two cell lines. In MDA-MB-231 cells, the combined treatment shows enhanced effects on lipid peroxidation, mitochondrial potential, and basal and maximal respiration, as compared to single treatments. Finally, ferroptosis expression signatures distinguish breast cancer cell lines with an increasing score in mesenchymal-like cells. Moreover, the signatures correlate with breast cancer subtypes, exhibiting the highest scores in subtypes rich in mesenchymal-like cells, particularly basal-like and claudin-low tumors, suggesting their susceptibility to ferroptosis induction.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 5","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400208","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer, a prevalent malignancy worldwide, includes the triple-negative subtype (TNBC) characterized by poor treatment outcomes. TNBC has been shown to be sensitive to ferroptotic cell death, an iron-dependent cell death mechanism involving reactive oxygen species (ROS) and lipid peroxidation. Herein, biodegradable tetraphenylchlorin-conjugated chitosan nanoparticles (TPC-CS NPs) in combination with the free ferroptosis inducer RSL3 is used in MCF7 (hormone receptor-positive, epithelial) and MDA-MB-231 (hormone receptor-negative, mesenchymal-like) breast cancer cell lines. The results show that RSL3 treatment has no cytotoxic effect in MCF7 and there is no enhanced sensitivity when combined with TPC-CS NPs, while the combination sensitizes MDA-MB-231 cells. Western blot analysis reveals that the combined treatment decreases and differently affects GPX4 levels and the ratio between the two GPX isoforms in the two cell lines. In MDA-MB-231 cells, the combined treatment shows enhanced effects on lipid peroxidation, mitochondrial potential, and basal and maximal respiration, as compared to single treatments. Finally, ferroptosis expression signatures distinguish breast cancer cell lines with an increasing score in mesenchymal-like cells. Moreover, the signatures correlate with breast cancer subtypes, exhibiting the highest scores in subtypes rich in mesenchymal-like cells, particularly basal-like and claudin-low tumors, suggesting their susceptibility to ferroptosis induction.
期刊介绍:
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.